Illustrative image – not actual.Pharmaceutical major AstraZeneca Plc
plans to invest $5 million in India per year from 2001 to 2005.
The proposed annual investment would be
in addition to the $10 million being invested in the company’s R&D facility
in Bangalore, which would henceforth focus only on tuberculosis (TB) research
programme. The R&D facility would focus on understanding the mechanism by
which the TB microbe evades the immune system and the prevailing treatments by
using the latest technology.
The company plans to undertake
clinical research in a major way in India.
